Secondary analysis of a phase III trial in 524 patients with unresectable or metastatic urothelial carcinoma: adding nivolumab to gemcitabine-cisplatin was non-inferior for global health status/QoL through week 16 vs gemcitabine-cisplatin alone.
Secondary analysisn = 524
Bedke et al. Nivolumab plus gemcitabine-cisplatin for unresectable or metastatic urothelial carcinoma: health-related quality-of-life analyses from the phase III CheckMate 901 trial